Publications in collaboration with researchers from Queen Mary University of London (17)

2024

  1. Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals

    Neurology and Therapy, Vol. 13, Núm. 4, pp. 1015-1038

2023

  1. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21

  2. Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis

    Digital Health, Vol. 9

  3. European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs

    European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176

  4. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary

    Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 5-13

  5. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69

  6. Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care

    Advances in Therapy, Vol. 40, Núm. 12, pp. 5131-5136

2022

  1. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

    Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846

  2. Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants

    Multiple Sclerosis and Related Disorders, Vol. 64

  3. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456

  4. Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis

    Multiple Sclerosis Journal

2021

  1. Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice

    Therapeutic Advances in Neurological Disorders, Vol. 14

  2. Multiple sclerosis progression discussion tool usability and usefulness in clinical practice: Cross-sectional, web-based survey

    Journal of Medical Internet Research, Vol. 23, Núm. 10

2019

  1. Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care

    Advances in Therapy, Vol. 36, Núm. 11, pp. 3238-3252

2018

  1. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

    The Lancet, Vol. 391, Núm. 10127, pp. 1263-1273

  2. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group

    Multiple Sclerosis and Related Disorders, Vol. 19, pp. 153-160

2015

  1. Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group

    Multiple Sclerosis and Related Disorders, Vol. 4, Núm. 3, pp. 202-218